STAGE IV PROSTATE CANCER AJCC V8

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, ivuxolimab, or radiation) in 173 people with advanced cancers that have not responded to standard therapies. The goal is to find tolerable doses and see i…

This phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This early-phase trial tests a new type of immunotherapy called PSCA-CAR T cells in 14 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment involves taking a patient's own immune cells, engineer…

This study tests a two-step treatment for men with aggressive prostate cancer that has spread. First, patients receive chemotherapy plus an immunotherapy drug. Then, they take a maintenance pill (niraparib) with or without more immunotherapy. The goal is to see if this approach c…

This study tests whether adding rucaparib to standard enzalutamide helps men with metastatic prostate cancer that has stopped responding to hormone therapy. About 61 men will receive either the combination or enzalutamide alone. The goal is to see if the combo slows cancer growth…

This early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…

This study tests whether combining two drugs, golimumab and apalutamide, can help men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if this combination can lower PSA levels by at least 50%. Eight participants are e…

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in adults with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the disease. About 65 particip…

This study tests whether adding an experimental drug (M6620) to standard chemotherapy can better shrink tumors or slow the disease in men with advanced prostate cancer that no longer responds to hormone therapy. About 73 participants will receive either M6620 plus carboplatin or …

This study tests whether combining two drugs, vidutolimod and nivolumab, can help the immune system attack and destroy prostate cancer cells that have spread to other parts of the body. The trial is for men with metastatic castration-resistant prostate cancer who have already tri…

This study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely pause treatment. About 79 men will stop their medications under doctor guidance to see if their testosterone levels recover and they remain cancer-free for at le…

This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men whose prostate cancer has spread but who have not yet received hormone therapy. The goal is to see how long patients can stay on treatment and to measure cancer progression and side…